Biophytis (EPA:ALBPS)

BRIEF

published on 03/11/2026 at 08:05, 29 days 12 hours ago

Biophytis Completes €2.0 Million Capital Increase

Biophytis Clinical Trials Capital Increase Sarcopenia Convertible Debt
REGULATED PRESS RELEASE

published on 03/11/2026 at 08:00, 29 days 12 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF OVER €2.0 MILLION CAPITAL INCREASE AND THE REPAYMENT OF ALL VARIABLE PRICE CONVERTIBLE DEBT
Biophytis completes over €2.0 million capital increase and repays all variable price convertible debt, attracting investments from U.S. healthcare institutions and strengthening financial structure for clinical development in sarcopenia and obesity

Biophytis Healthcare Institutions Capital Increase Clinical Development Convertible Debt
BRIEF

published on 02/27/2026 at 23:05, 1 month 9 days ago

Biophytis Expands Bond Facility with Hexagon Capital to €2 Million

Biophytis Clinical Development Financial Strategy Hexagon Capital Bond Facility
REGULATED PRESS RELEASE

published on 02/27/2026 at 23:00, 1 month 9 days ago

Biophytis increases to €2 million the ceiling of its bond facility with Hexagon Capital Fund
Biophytis increases its bond facility ceiling to €2 million with Hexagon Capital Fund, extending subscription period and strengthening financial structure

Biophytis Financial Structure Subscription Period Hexagon Capital Fund Bond Facility
PRESS RELEASE

published on 02/27/2026 at 22:59, 1 month 9 days ago

Biophytis increases to €2 million the ceiling of its bond facility with Hexagon Capital Fund
Biophytis increases bond facility to €2 million with Hexagon Capital Fund, extending subscription period. CEO and Director comment on the partnership

Biophytis Clinical Development Finance Hexagon Capital Fund Bond Facility
BRIEF

published on 01/28/2026 at 07:35, 2 months 12 days ago

Biophytis Secures $20 Million for Sarcopenia Phase 3 Trial in Asia

Biophytis Joint Venture Phase 3 Trial Sarcopenia Asian Markets
REGULATED PRESS RELEASE

published on 01/28/2026 at 07:30, 2 months 12 days ago

Biophytis enters strategic agreement in Asia and secures $20 million for launch of Phase 3 trial in sarcopenia
Biophytis announces strategic agreement in Asia and secures $20 million for Phase 3 trial in sarcopenia, including creation of joint venture in Hong Kong and financing over 3 years

Biophytis Joint Venture Phase 3 Trial Sarcopenia Strategic Agreement
BRIEF

published on 01/12/2026 at 09:05, 2 months 28 days ago

Biophytis to Engage in Major Healthcare and Investment Events

Biophytis BIOMED Forum Longevity Therapies Healthcare Investment JP Morgan Healthcare
REGULATED PRESS RELEASE

published on 01/12/2026 at 09:00, 2 months 28 days ago

Biophytis to Participate in the JP Morgan Healthcare Conference and the Biomed Forum
Biophytis announces participation in JP Morgan Healthcare Conference and Biomed Forum in January 2026, presenting latest operational and clinical progress

Biophytis BIOMED Forum Age-related Diseases JP Morgan Healthcare Conference Transformative Therapies
PRESS RELEASE

published on 01/12/2026 at 08:59, 2 months 28 days ago

Biophytis to Participate in the JP Morgan Healthcare Conference and the Biomed Forum
Biophytis to participate in JP Morgan Healthcare Conference and Biomed Forum to engage with global financial and pharmaceutical communities for 2026 outlook

Biophytis BIOMED Forum Healthcare Conference JP Morgan 2026

Published on 04/09/2026 at 19:15, 53 minutes ago

Murchison Minerals Announces Adoption of Quarterly Reporting Exemption Under Coordinated Blanket Order 51-933
Published on 04/09/2026 at 16:00, 4 hours 8 minutes ago

Banff Half Marathon Completes 2025 Emissions Assessment, Supporting Climate Action with Karbon-X
Published on 04/09/2026 at 14:40, 5 hours 28 minutes ago

Silver X Delivers Production Growth During the First Quarter of 2026
Published on 04/09/2026 at 14:00, 6 hours 8 minutes ago

Orogen Royalties Announces Mineral Reserve and Resource Update on Producing Ermitaño Royalty
Published on 04/09/2026 at 13:30, 6 hours 38 minutes ago

Datametrex Receives $6M Purchase Order for Data Centre from Fortune 500 Conglomerate

View all ACCESSWIRE

Published on 04/09/2026 at 18:15, 1 hour 53 minutes ago

REPLY: Launch of a share buyback program for a maximum number of 3,607,950 shares
Published on 04/09/2026 at 15:59, 4 hours 9 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 04/09/2026 at 15:57, 4 hours 11 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 04/09/2026 at 15:40, 4 hours 28 minutes ago

Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
Published on 04/09/2026 at 15:39, 4 hours 29 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc

View all EQS

Published on 04/09/2026 at 18:35, 1 hour 33 minutes ago

Availability of proxy documents for the Combined General Meeting of April 30, 2026
Published on 04/09/2026 at 17:35, 2 hours 33 minutes ago

SUEZ - FY 2025
Published on 04/09/2026 at 15:57, 4 hours 11 minutes ago

Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 13 hours 8 minutes ago

bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Published on 04/08/2026 at 18:02, 1 day 2 hours ago

Publication of the 2025 Universal Registration Document

View all LES ECHOS COMFI WIRE

News